CLINDAMYCIN oral

Prescription under medical supervision

Therapeutic action

– Lincosamide antibacterial

Indications

– Severe staphylococcal and/or streptococcal infections (e.g. erysipelas, cellulitis, cutaneous anthrax, pneumonia):
• in betalactam-allergic patients
• in infections due to methicillin-resistant Staphylococcus aureus
– Completion treatment following parental therapy with clindamycin

Forms and strengths

– 150 mg and 300 mg capsules

Dosage

– Child: 10 to 13 mg/kg 3 times daily 
– Adult: 600 mg 3 times daily

Age

Weight

150 mg capsule

300 mg capsule

1 to < 6 years

10 to < 20 kg

1 cap x 3

6 to < 9 years

20 to < 30 kg

1 cap x 3

9 to < 13 years

30 to < 45 kg

3 cap x 3

≥ 13 years and adult

≥ 45 kg

2 cap x 3

Duration

 Erysipelas, cellulitis: 7 to 10 days; cutaneous anthrax: 7 to 14 days depending on severity; pneumonia: 10 to 14 days

Contra-indications, adverse effects, precautions

– Do not administer to patients with allergy to lincosamides or history of pseudomembranous colitis.
– Reduce dosage in patients with hepatic impairment.
– May cause: pseudomembranous colitis, rash, jaundice, severe allergic reactions. In these cases, stop treatment.
– In the event of pseudomembranous colitis, treat for Clostridium difficile infection (oral metronidazole).
– Do not administer simultaneously with antacids (aluminium or magnesium hydroxide, etc.). Administer 2 hours apart.
– Pregnancy: no contra-indication
– Breast-feeding: use only when there is no therapeutic alternative. Check infant’s stools (risk of pseudomembranous colitis).

Remarks

– Capsules are not suitable for children under 6 years (risk of aspiration). Open the capsule and mix the content into a spoon with food or fruit juice to mask the unpleasant taste.
– Clindamycin is use in combination with quinine for the treatment of malaria in pregnant women (10 mg/kg 2 times daily for 7 days).
– Also comes in 75 mg/5 ml oral suspension.
– Storage: below 25 °C -  -